Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05296070 · ClinicalTrials.gov registry record · Phase 2
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
A Phase 2 study of Marginal Zone Lymphoma, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 4
- Study locations
NCT05296070: Recruiting Phase 2 study of Marginal Zone Lymphoma, sponsored by University of Miami.
NCT05296070 is a Phase 2 study of Marginal Zone Lymphoma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 50 participants, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (51% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05296070, a Phase 2 study of Marginal Zone Lymphoma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on the participant and the participant's condition.
Primary Outcome
CR rate is defined as the Complete Response (CR)/n, where n is the number of participants. The proportion of patients with best overall response of complete response (CR), per Cheson criteria if disease is not PET (Positron emission tomography)-avid in initial screening and by revised Lugano criteria if screening PET-CT demonstrated PET-avid disease.CR will be defined by a Deauville score of ≤ 3.
Conditions Studied
Interventions
- DRUG Loncastuximab tesirine 150 µg/Kg
- DRUG Loncastuximab tesirine 75µg/Kg
Study Locations (4)
California
- City of Hope National Medical Center - Duarte
Florida
- University of Miami - Miami
Georgia
- Emory University - Atlanta
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
What NCT05296070 shows while recruiting
NCT05296070 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Marginal Zone Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Loncastuximab tesirine 150 µg/Kg is the first listed.
NCT05296070 reports a single indexed study location in California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05296070 about?
NCT05296070 is a clinical study titled "Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma". The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on...
What is the current status of trial NCT05296070?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-06-21. Estimated completion is 2029-06-30.
What conditions does trial NCT05296070 study?
This clinical trial studies the following conditions: Marginal Zone Lymphoma.
What interventions are being tested in trial NCT05296070?
The interventions under investigation include: Loncastuximab tesirine 150 µg/Kg (DRUG), Loncastuximab tesirine 75µg/Kg (DRUG).
Who is sponsoring clinical trial NCT05296070?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05296070 being conducted?
This trial has 4 study locations across California, Florida, Georgia, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marginal Zone Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05296070's enrollment target sits among peer trials
50 21st of 49 higher than 28 of 49 other Marginal Zone Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Marginal Zone Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
-
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
RECRUITING · Phase 2
-
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI